Mark Your Calendar: RESI Boston Summer on June 4th, 2018

By Samuel Rubin, Business Development Manager, LSN

Life Science Nation (LSN) and the RESI Conference now sets its sights on RESI Boston on June 4th, the day before the annual BIO Convention. This is the second year in a row LSN is holding a RESI Conference during BIO week, which promises to bring more than 15,000 life science executives to Boston. RESI specializes in early stage investor partnering, touting hundreds of qualified investment firms interested in meeting with innovative life science startups. No other Conference has such a deeply-rooted focus on early stage investment, complete with a robust data platform to connect with only those firms who are the right match. RESI will therefore offer significant value to folks traveling to BIO looking for something to do the Monday before BIO kicks off.

Registration is now open at the Early Bird Rate. If you would like to learn more about RESI Boston and why it’s a great choice for incorporating into your summer fundraising plans, don’t hesitate to contact us.

Click here to learn more about Premier Partnering Plus

RESI Lands on MaRS in 5 Days – Check out the Program Guide

By Nono Hu, Director of Marketing, LSN

In 5 days, The Redefining Early Stage Investments (RESI) Conference will return to MaRS Discovery Centre, Toronto for the third time during the Toronto Health Innovation Week. So far, we have over 700 meetings booked through the RESI Partnering Platform, and have registered over 250 early stage investors.

If you’re planning your day at RESI on MaRS, check out the program guide now to find the full lineup of speakers, innovators, exhibitors and sponsors.

See you at MaRS on April 10th!

Why MaRS Toronto for an International Early Stage Investor Conference?

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

There is a rich diversity of technology assets being developed in Toronto, as MaRS Discovery District and Johnson & Johnson’s JLABS have convened to create one of the most dynamic centers for life science technology innovation in North America. However, not to use an old cliché, Toronto’s real value in life science is in the people, from its visionary leaders to its extraordinary scientist-entrepreneurs, all striving (and succeeding) to move the needle and create the next generation of healthcare innovation.

When I first launched the Redefining Early Stage Investments (RESI) Conference in Toronto in 2016, my network of global early-stage investors were initially open to seeing what was up in the north country. Just two years and three Toronto RESI conferences later, I am witnessing unprecedented signups from the global investor community. Much to my amazement, this upcoming RESI conference (April 10th at MaRS Discovery Centre) has seen a 25% increase in investor and strategic partner registrations. We expect 300-350 qualified investors (all with vetted investment mandates) to peruse the lineup of hundreds of early-stage biotech, medtech, diagnostics and digital health startups. But one quite compelling factor is that we expect that almost 60% of the investors and partners will be from outside of Canada.

But I digress. Back to the people factor. What I learned from discussion with investors who have attended RESI on MaRS in the past was actually quite startling. The main takeaway from a majority of the investors I chatted with was that the caliber of the fundraising CEOs and scientist-entrepreneurs was the main differentiator. It was their genuineness and their lack of inflated value of their technology that impressed the investors. In contrast, the Boston, NYC and CA players had elevated expectations regarding the amount of time it takes to get a deal done, and the valuations of their assets were off the charts. The investors implied that if they find a deal they like in Toronto, the valuations and executive teams in Canada are much more realistic, which translates into getting contracts signed quicker. These perceptions impact and ignite the global investor community and have heightened interest in Toronto, which proves out the adage that if you build it, they will come!

 

Meet the Family Office Panelists at RESI Toronto

By Christine A. Wu, Senior Research Analyst, LSN

chrsitine

For every RESI event, the LSN Investor Research team aims to recruit a diverse slate of panels with experienced investors of all types and focus areas within life science technology. As one of the more highly sought types of investors for entrepreneurs, Family Offices is a recurring panel at RESI. Mostly backed by private wealth as evergreen funds, family offices often have deep connections in the life science field both professionally and, at times, personally—some family office investors have loved ones battling debilitating diseases. Family offices are highly idiosyncratic with their own motivations and strategies, though despite their differences and founding stories, they continue to play actively within life science investment.

On April 10th at RESI Toronto, we will hear from four family offices that invest in several different life science sectors. Moderated by Catherine Love, Director of Capital Services for MaRS Discovery District, the panelists include:

  • Sherry Grisewood, Chief Investment Office, Foxhill Asset Management
  • David Ramos, CFO, AGP Holdings
  • Chuck Stetson, CEO, Stetson Family Office
  • Oded Levi, President, Epstein Enterprises

Register now for RESI Toronto at the MaRS Discovery District on April 10th to hear from these experienced individuals.

RESI Toronto 2018 Sponsors and Exhibitors List

By Sean Tran, Business Development Manager, LSN

The Life Science Nation team is pleased to announce the sponsors and exhibitors for our third RESI conference in Toronto. Attracting over 600 attendees, sponsors and exhibitors will be in the spotlight of our exhibition hall, standing out as leaders in the life science industry.

Twenty companies will participate in the Exhibition, displaying their products and services. The array of offerings from these exhibitors will give attending companies a chance to meet valuable partners to help move their technologies forward in development.

Exhibitors

Title Sponsors

Gold Sponsors

Silver Sponsors

Bronze Sponsors

MaRS Supporters

Media Sponsors

 

Thank you for your support of the conference and your commitment to the continual advancement of the healthcare industry.

RESI on MaRS Panel Announcement: Venture Philanthropy

By James Huang, Research Analyst, LSN

james-wp

RESI endeavors to bring a diverse pool of investors to each of our events for early stage life science companies. Among them are venture philanthropic foundations whose profound expertise within their targeted disease areas makes them great resources for any entrepreneur looking to work within their areas of expertise. Additionally, venture philanthropic investors tend to focus on assets at an earlier stage than typical VCs, with the aim of helping new treatments traverse the infamous “Valley of Death.”

LSN is pleased to announce a panel of five venture philanthropic investors for the upcoming RESI on MaRS this April 10th in Toronto. In this panel, these investors will explain their unique strategies and expertise, and entrepreneurs can learn how to find and work with a venture philanthropy investor in their domain. RESI attendees will have the exclusive opportunity to hear from:

RESI on MaRS Panel Announcement: Diagnostics Investors

By Claire Jeong, Research Analyst, LSN

claire

The field of diagnostics can be a difficult space to navigate due to challenges in the regulatory and reimbursement processes that hinder successful commercialization. However, the implications of diagnostic technologies can be enormous; from precision genomics that enable optimum health management and personalized care to novel biomarkers that can successfully detect high mortality diseases in its earliest stages, diagnostics companies are developing some of the most highly disruptive technologies in the industry.

In this session, we invite 5 investors with strong expertise in this diverse space to speak about their unique approaches in working with early-stage companies. Investors will discuss the types of investment opportunities they seek and share valuable insights on building long lasting relationships, differentiating your technology from similar competitors, and more. We hope you will be able to join us for the RESI Toronto Conference in the MaRS Innovation Center on April 10th to meet these awesome panelists!

Moderated by Drew Taylor, Lead Medical Researcher, Epic Capital Management, the panel participants are:

  • Yiu-Lian Fong, Innovation Lead for Diagnostics, Johnson & Johnson (Medical Devices)
  • Kelly Holman, Co-Founder & Managing Director, Genesys Capital
  • Yvan Côté, General Manager of Dynacare Next & Orchid PRO-DNA, Dynacare
  • Amine Benmoussa, Principal (Healthcare), BDC Healthcare Fund